Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder

There will be 400 adults with moderate or severe methamphetamine use disorder randomized into
this multi-site study. Eligibility will be determined during a maximum 21 day screening
period. After screening is completed and eligibility is confirmed, including successful
administration of a naloxone challenge, participants will begin the 12 week medication phase
of the trial. Participants will be randomized to either the 1) AMC arm and receive injections
of extended release naltrexone (XR-NTX; as Vivitrol®) plus once-daily oral extended-release
bupropion tablets (BUP-XL) or the 2) matching placebo (PLB) arm and receive injections of
placebo (iPLB) plus once-daily oral placebo (oPLB) tablets. During the course of the study,
participants may be switched to another arm, as determined by the a priori adaptive aspect of
the study design. Participants appearing to respond well to their original treatment
assignment will not be switched. Overall, approximately 50% of the participants will receive
the AMC. Injections will be administered every three weeks, in weeks 1, 4, 7, and 10.
Take-home oral study medication (BUP-XL or oPLB) will be dispensed weekly for dosing on
non-clinic days. Participants will be asked to attend the clinic twice weekly for observed
oral medication dosing, assessments, collection of urine samples, and once-weekly medical
management. On non-clinic days, participants will participate in smartphone app-based
medication adherence activities. Participants will be asked to complete assessments as
indicated on the schedule of assessments. Following the 12 week medication phase,
participants will complete a follow-up phase, including a medication taper and
post-medication phase follow-up visits during weeks 13 and 16.

Inclusion Criteria:

- 18 to 65 years old;

- Interested in reducing/stopping methamphetamine use;

- Speak English;

- Agree to use acceptable birth control (if applicable);

- Be opioid-free at randomization;

- Willing to comply with all study procedures and medication instructions;

- Agree to use a cell phone (or similar study device) to take videos of medication
dosing.

Exclusion Criteria:

- Medical or psychiatric condition which would make participation unsafe;

- Recently participated in a study of pharmacological or behavioral treatment for
methamphetamine use disorder;

- Recently taken an investigational drug;

- Prescribed and taken naltrexone or bupropion ≤ 30 days from consent;

- Current or planned extended absence during study period (e.g., jail, surgery, pending
legal action);

- Currently pregnant or breastfeeding.